Bolton LP’s Myriad Genetics MYGN Stock Holding History

Bolton LP’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-52,500	Closed	-$1.79M	–	124
2014 Q4	$1.79M	Hold	52,500	–	–	0.55%	42
2014 Q3	$2.02M	Hold	52,500	–	–	0.42%	45
2014 Q2	$2.04M	Buy	+52,500	New	+$1.95M	0.31%	50
2014 Q1	–	Sell	-706	Closed	-$827K	–	226
2013 Q4	$827K	Buy	+706	New	+$17.9K	0.15%	74

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BTS

BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bolton LP's MYGN Position: Q1 2015 in Review

Bolton LP sold out of Myriad Genetics (MYGN) in Q1 2015, closing a stake of 50,000 shares — an estimated $1.7M sold.

Bolton LP first reported a position in MYGN in Q4 2013 and held it in 5 quarters. The position peaked at $2.19M in Q1 2014. 251 funds tracked by Wall St. Rank hold MYGN as of Q1 2015.

Bolton LP reported no remaining Myriad Genetics position as of Q1 2015 after selling out during the quarter.
Bolton LP sold 50,000 Myriad Genetics shares in Q1 2015, an estimated $1.7M.
Bolton LP first reported a position in Myriad Genetics in Q4 2013 and held it in 5 quarters.
Bolton LP's Myriad Genetics position peaked at $2.19M in Q1 2014.
251 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2015.

Based on Bolton LP's 13F filing for Q1 2015, filed 15 May 2015.